Absence of association between individual thymidine analogues or nonnucleoside analogues and lipid abnormalities in HIV-1-infected persons on initial therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 24, Issue 4, 2000, Pages 310-315

  Matthews, G V ^a   Moyle, Graeme J ^a   Mandalia, S ^a   Bower, M ^a   Nelson, M ^a   Gazzard, B G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Lipid abnormalities; Nonnucleoside analogues; Thymidine analogues

Indexed keywords

ANTIRETROVIRUS AGENT; CHOLESTEROL; DIDANOSINE; EFAVIRENZ; FAT; LAMIVUDINE; LIPID; NEVIRAPINE; NUCLEOSIDE ANALOG; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; THYMIDINE DERIVATIVE; TRIACYLGLYCEROL; ZIDOVUDINE;

ADIPOCYTE; ADULT; AGE; ARTICLE; ATHEROGENESIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; TRIACYLGLYCEROL BLOOD LEVEL; VIRUS LOAD;

EID: 0034253091     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200008010-00002     Document Type: Article

References (21)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency vires infection
2. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
3. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlidaemia, and insulin resistance
4. Metabolic abnormalities and use of HIV-1 protease inhibitors
5. Fat accumulation and HIV-1 protease inhibitors
6. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy
7. Nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophy
8. Lipodystrophy in patients naive to protease inhibitors
9. Lipodystrophy associated with nevirapine-containing antiretroviral therapies
10. Metabolic complications and body fat re-distribution in HIV-1 infected individuals: The fat redistribution syndrome
11. Protease inhibitors and nucleoside analogue reverse transcriptase inhibitors interact to cause subcutaneous fat wasting in patients with HIV infection
12. A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving longterm nucleoside analogue therapy
13. Incidence of lipodystrophy in START (selection of thymidine analog regimen therapy) studies
14. Reversibility of peripheral fat wasting (lipoatrophy) on stopping stavudine therapy
15. Stavudine use is not associated with an increased incremental risk of hyperlipidaemia during treatment with HIV-1 protease inhibitors
16. Biological variation in serum lipid concentrations
17. Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: Lactic acidosis, risk factors and therapeutic options